| Experiment name | Clinical attributes |
| Boldrick02_Diversity_Dataset_Bp338_timecourse_0_0_hr | Lymphocytes (Stimulated PBMC*), Monocytes (Stimulated PBMC*), Primary blood mononuclear cells (Stimulated PBMC*), Hematologic samples (Stimulated PBMC*), Hematologic samples and cell lines (Stimulated PBMC*), Unstimulated immune cells (Stimulated PBMC) |
| Boldrick02_Diversity_Dataset_Untreated_timecourse_2_0_hr | Lymphocytes (Stimulated PBMC*), Monocytes (Stimulated PBMC*), Primary blood mononuclear cells (Stimulated PBMC*), Hematologic samples (Stimulated PBMC*), Hematologic samples and cell lines (Stimulated PBMC*), Unstimulated immune cells (Stimulated PBMC) |
| Boldrick02_Dose_Response_Dataset_Bp338_100X_dose_timecourse_4_0hr | B. petrussis stimulated immune cells (Stimulated PBMC), Gram negative bacteria stimulated immune cells (Stimulated PBMC), B. petrussis 338 stimulated immune cells (Stimulated PBMC), Lymphocytes (Stimulated PBMC*), Monocytes (Stimulated PBMC*), Primary blood mononuclear cells (Stimulated PBMC*), Stimulated immune cells (Stimulated PBMC*), Hematologic samples (Stimulated PBMC*), Hematologic samples and cell lines (Stimulated PBMC*) |
| Boldrick02_Dose_Response_Dataset_Bp_LPS_0_01ug_ml_timecourse_2_0hr | Lymphocytes (Stimulated PBMC*), Monocytes (Stimulated PBMC*), Primary blood mononuclear cells (Stimulated PBMC*), Stimulated immune cells (Stimulated PBMC*), Hematologic samples (Stimulated PBMC*), Hematologic samples and cell lines (Stimulated PBMC*), Lipopolysaccharide (LPS) stimulated immune cells (Stimulated PBMC), 1X dose immune stimulation (Stimulated PBMC) |
| Garber01_230_97_SCLC | Cancer (Lung cancer*), Cancer and cell line (Lung cancer*), Lung tissue, cancer or cell line (Lung cancer*), Lung cancer (Lung cancer*), Lung cancer or cell line (Lung cancer*), Small cell lung cancer (Lung cancer) |
| Perou00_BC711A_AF | Breast tissue, cancer or cell line (Breast cancer*), Breast cancer or cell line (Breast cancer*), Cancer and cell line (Breast cancer*), Female hormonal cancer or cell line (Breast cancer*), Female hormonal tissue, cancer or cell line (Breast cancer*), After doxorubicin chemotherapy (Breast cancer), Adenocarcinoma (Breast cancer*), Breast cancer (Breast cancer*), Cancer (Breast cancer*), Breast tissue or cancer (Breast cancer*), Female hormonal cancer (Breast cancer*), Female hormonal tissue or cancer (Breast cancer*) |
| Perou00_BT_474_ATCC | Breast cancer cell line (Breast cancer), Epithelial cell line (Breast cancer), Female hormonal cancer cell line (Breast cancer), Cell line (Breast cancer), Breast tissue, cancer or cell line (Breast cancer*), Breast cancer or cell line (Breast cancer*), Cancer and cell line (Breast cancer*), Female hormonal cancer or cell line (Breast cancer*), Female hormonal tissue, cancer or cell line (Breast cancer*) |
| Perou00_MDA_MB_231_NCI | Cell line (Breast cancer), Breast cancer or cell line (Breast cancer*), Cancer and cell line (Breast cancer*), Mesenchemal cell line (Breast cancer) |
| Perou00_SW872 | Cell line (Breast cancer), Cancer and cell line (Breast cancer*), Mesenchemal cell line (Breast cancer) |
| Rosenwald01_CLL_58 | Lymphocytes (B lymphoma*), Hematologic cancer and cell line (B lymphoma*), Cancer and cell line (B lymphoma*), B cells (B lymphoma*), Hematologic cancer (B lymphoma*), Cancer (B lymphoma*), Chronic lymphocytic leukemia (B lymphoma), Leukemia (B lymphoma), Leukemia or leukemia cell line (B lymphoma) |
| Ross00_HCC_2998_CL4002_COLON | Colon cancer cell line (NCI60), Fast doubling (20-40) cell lines (NCI60), Colon tissue, cancer or cell line (NCI60), Colon cancer or cell line (NCI60), Cell line (NCI60*), Cancer and cell line (NCI60*) |
| Ross00_MDA_MB_435_CL5011_BREAST | Fast doubling (20-40) cell lines (NCI60), Cell line (NCI60*), Cancer and cell line (NCI60*), Breast cancer cell line (NCI60), Female hormonal cancer cell line (NCI60), Breast cancer or cell line (NCI60), Breast tissue, cancer or cell line (NCI60), Female hormonal tissue, cancer or cell line (NCI60) |
| Ross00_UACC_257CL10021_MELANOMA | Fast doubling (20-40) cell lines (NCI60), Cell line (NCI60*), Cancer and cell line (NCI60*), Melanoma cell line (NCI60), Melanoma tumor or cell line (NCI60) |
| Ross01_MCF7_UCLA | Cell line (NCI60*), Cancer and cell line (NCI60*), Breast cancer cell line (NCI60), Female hormonal cancer cell line (NCI60), Breast cancer or cell line (NCI60), Breast tissue, cancer or cell line (NCI60), Female hormonal tissue, cancer or cell line (NCI60) |
| Sorlie01_BC107B_BE | Breast tissue, cancer or cell line (Breast cancer*), Breast cancer or cell line (Breast cancer*), Cancer and cell line (Breast cancer*), Female hormonal cancer or cell line (Breast cancer*), Female hormonal tissue, cancer or cell line (Breast cancer*), Adenocarcinoma (Breast cancer*), Breast cancer (Breast cancer*), Cancer (Breast cancer*), Breast tissue or cancer (Breast cancer*), Female hormonal cancer (Breast cancer*), Female hormonal tissue or cancer (Breast cancer*), Estogen receptor (ER) positive breast cancer (Breast cancer), Breast cancer - (prognostic) relapse (Breast cancer), Mutated p53 tumor (Breast cancer) |
| Sorlie01_BC305A_BE | Breast tissue, cancer or cell line (Breast cancer*), Breast cancer or cell line (Breast cancer*), Cancer and cell line (Breast cancer*), Female hormonal cancer or cell line (Breast cancer*), Female hormonal tissue, cancer or cell line (Breast cancer*), Adenocarcinoma (Breast cancer*), Breast cancer (Breast cancer*), Cancer (Breast cancer*), Breast tissue or cancer (Breast cancer*), Female hormonal cancer (Breast cancer*), Female hormonal tissue or cancer (Breast cancer*), Estogen receptor (ER) positive breast cancer (Breast cancer), Dead prognosis (Breast cancer), Breast cancer - (prognostic) relapse (Breast cancer), Mutated p53 tumor (Breast cancer) |